AGP Executive Report
Last update: 8 hours agoCardiovascular Drug Setback: Novartis and Ionis’ pelacarsen (an RNA therapy targeting Lp(a)) missed its Phase 3 goal, failing to reduce heart attacks, strokes, or death despite lowering Lp(a) levels—raising questions for the next wave of heart-protection strategies. Health Plan Network Shock: Mass General Brigham Health Plan is removing Dana-Farber from its Medicare Advantage network, leaving about 1,000 patients facing coverage changes after a 90-day transition. Mental Health Access: Vermont opened the Asha Clinic in Burlington, a specialized outpatient program focused exclusively on suicide care, led by suicide researcher Dr. Craig Bryan. Public Health & Safety: Kentucky received $213M for rural health upgrades, while a UK rabies-vaccine batch was flagged as substandard by regulators—prompting a manufacturer response about supply-chain release. Clinical Tech in Oncology: New talks highlight how AI is being used to streamline tumor boards and treatment planning, plus open-source tools for PSMA PET/CT segmentation. Weight-Loss Counterfeit Warning: UK reporting says illicit copycat retatrutide is circulating widely despite the drug not being approved for human use. Food & Pharma Compliance: India’s drug regulator seized potentially spurious rabies vaccine vials, and a US antitrust settlement has Zydus Pharmaceuticals USA paying $5.9M to resolve pricing litigation.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
